Neurochem, Nycomed in diagnostics deal

The companies will develop a product for diagnosing Alzheimer's disease. Neurochem (TSE:NRM) will identify amyloid-binding molecules and Nycomed Amersham Imaging (London, U.K.) will then synthesize ra...